AACE/ACE Consensus StatementConsensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary
Cited by (0)
This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.
Address correspondence to American Association of Clinical Endocrinologists, 245 Riverside Avenue, Suite 200, Jacksonville, FL 32202. E-mail: [email protected].
DISCLOSURES
Chair of the Task Force
Dr. Alan J. Garber: reports no potential conflicts of interest.
Task Force Members
Dr. Martin Julian Abrahamson: Novo Nordisk, consultant.
Dr. Joshua I. Barzilay; Dr. Jeffrey R. Garber; Dr. Susan L. Samson: report no potential conflicts of interest.
Dr. Lawrence Blonde: AstraZeneca, Gilead Sciences, Inc., Merck, Janssen Pharmaceuticals, Novo Nordisk, Sanofi, consultant; Sanofi, Janssen Pharmaceuticals, Novo Nordisk, speaker; Novo Nordisk, Sanofi, research grant support.
Dr. Michael A. Bush: Eli Lilly, Novo Nordisk, AstraZeneca, Janssen, speaker and/or consultant.
Dr. Ralph Anthony DeFronzo: Novo Nordisk AstraZeneca, speaker; Boehringer Ingelheim, Janssen Pharmaceuticals, Merck and AstraZeneca, research grant support; Advisory Board: Novo Nordisk, Astra Zeneca, Janssen, Intarcia.
Dr. Daniel Einhorn: Novo Nordisk, Eli Lilly, Abbott, Sanofi, Janssen, AstraZeneca, Boehringer-Ingelheim, consultant, speaker and/or research grant support; Halozyme, stock ownership.
Dr. W. Timothy Garvey: Novo Nordisk, Boehringer-Ingelheim, BOYDSense, Sanofi, Gilead, Amgen, consultant; Pfizer, Sanofi, and Novo Nordisk, research grant support.
Dr. George Grunberger: Eli Lilly, Novo Nordisk, Sanofi, Boehringer Ingelheim, speaker; Medtronic, Novo Nordisk, research grant support.
Dr. Yehuda Handelsman: Amarin, AstraZeneca, BI-Lilly, Merck, Sanofi, consultant and/or speaker; Amgen, AstraZeneca, BMS, Gan & Lee, Mylan, Novo Nordisk, and Sanofi, research grant support.
Dr. Irl B. Hirsch: Abbott, Roche, Bigfoot, Becton Dickinson, consulting fees; Medtronic Diabetes, research grant support.
Dr. Paul S. Jellinger: Regeneron/Sanofi, Amgen, Janssen Pharmaceuticals, Merck, Amarin, AstraZeneca, speaker.
Dr. Janet B. McGill: Aegerion, consultant and/or speaker.
Dr. Jeffrey I. Mechanick: Abbott Nutrition International, consultant.
Dr. Leigh Perreault: Novo Nordisk, Sanofi, AstraZeneca, Merck, Boehringer-Ingelheim, and Janssen, consultant and/or speaker.
Dr. Paul D. Rosenblit: Akcea, Esperion, Novo Nordisk, consultant; Akcea, Amarin, Amgen, Merck, speaker; Amgen, Dexcom, GlaxoSmithKine, Ionis, Lilly, Mylan, Novo Nordisk, research grant support.
Dr. Guillermo E. Umpierrez: Sanofi, Dexcom, Novo Nordisk, research grant support.
Amanda M. Justice (medical writer) has received fees for medical writing from Asahi Kasei Pharma Corp, Lexicon Pharmaceuticals Inc, Metavant Sciences Inc, and Sanofi.